- Trials with a EudraCT protocol (91)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
91 result(s) found for: Exposure science.
Displaying page 4 of 5.
EudraCT Number: 2008-000349-68 | Sponsor Protocol Number: B0451004 | Start Date*: 2008-11-05 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York NY10017 | |||||||||||||
Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, MULTI-CENTER, DIABETIC MACULAR EDEMA DOSE RANGING, COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04523655 VERSUS LASER THERAPY (DEGAS) | |||||||||||||
Medical condition: Diabetic Macular Edema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002088-18 | Sponsor Protocol Number: H3A106104 | Start Date*: 2006-10-12 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy. | |||||||||||||
Medical condition: Narcolepsy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) FI (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016119-38 | Sponsor Protocol Number: 20090402 | Start Date*: 2010-05-19 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Rheumatoid Arthritis. | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) LV (Prematurely Ended) CZ (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005019-96 | Sponsor Protocol Number: 20101221 | Start Date*: 2014-09-11 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) | |||||||||||||
Medical condition: Immune Thrombocytopenia (ITP) in Paediatric Subjects | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) GB (Completed) HU (Completed) Outside EU/EEA PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004117-33 | Sponsor Protocol Number: H3B109689 | Start Date*: 2007-12-17 | |||||||||||
Sponsor Name:GlaxoSmithKline R&D Ltd | |||||||||||||
Full Title: A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selec... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002474-39 | Sponsor Protocol Number: VBN-01 | Start Date*: 2018-01-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Nykode Therapeutics AS | |||||||||||||||||||||||||||||||||
Full Title: An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy... | |||||||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002715-11 | Sponsor Protocol Number: CP001 | Start Date*: 2007-09-12 | ||||||||||||||||
Sponsor Name:Circassia Ltd | ||||||||||||||||||
Full Title: An Escalating Single Intradermal or Subcutaneous Dose Study in Cat Allergic Subjects to Assess the Safety of Cat-PAD | ||||||||||||||||||
Medical condition: Cat allergic rhinistis and asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004161-13 | Sponsor Protocol Number: ZN-c3-006 | Start Date*: 2022-04-24 | |||||||||||
Sponsor Name:K-Group Beta, Inc. | |||||||||||||
Full Title: A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer | |||||||||||||
Medical condition: Platinum-resistant Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001335-30 | Sponsor Protocol Number: N0S103325 | Start Date*: 2005-12-07 | |||||||||||
Sponsor Name:GlaxoSmithKline R&D | |||||||||||||
Full Title: A Multicentre, Two-Part, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy,Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up... | |||||||||||||
Medical condition: Prophylaxis of migraine headache | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) BE (Completed) FI (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000292-42 | Sponsor Protocol Number: TPL108390 | Start Date*: 2007-12-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to asses... | |||||||||||||
Medical condition: Thrombocytopenic subjects with hepatitis C viral infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GR (Completed) BE (Completed) ES (Completed) IT (Completed) CZ (Completed) SK (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002691-18 | Sponsor Protocol Number: CBA106809 | Start Date*: 2006-10-03 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development | |||||||||||||
Full Title: A multi-centre, randomised, single-blind, placebo-controlled, parallel group study to investigate the efficacy of single pre-emptive doses of GW842166X, a non-cannabinoid CB2 receptor agonist, on p... | |||||||||||||
Medical condition: Inflammatory Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) IT (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000384-26 | Sponsor Protocol Number: BPLG-005 | Start Date*: 2005-11-10 | |||||||||||
Sponsor Name:LG Life Science Ltd. [...] | |||||||||||||
Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency. | |||||||||||||
Medical condition: growth hormone deficiency in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004946-17 | Sponsor Protocol Number: TPL103922 | Start Date*: 2007-11-02 | |||||||||||
Sponsor Name:GlaxoSmithKline S.A. España | |||||||||||||
Full Title: Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... | |||||||||||||
Medical condition: Sujetos trombocitopénicos con infección vírica por Hepatitic C. Thrombocytopenic subjects with hepatitis C viral infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed) CZ (Completed) GB (Completed) SK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006458-91 | Sponsor Protocol Number: KU36-44 | Start Date*: 2007-05-22 | |||||||||||
Sponsor Name:KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies) | |||||||||||||
Full Title: A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associat... | |||||||||||||
Medical condition: Advanced breast cancer (stage IIIB/IIIC/IV) and confirmed BRCA+ status | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) ES (Ongoing) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004786-40 | Sponsor Protocol Number: PB-102-F01 | Start Date*: 2013-05-10 | |||||||||||
Sponsor Name:Protalix Ltd. | |||||||||||||
Full Title: A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks ... | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000603-91 | Sponsor Protocol Number: CA013-004 | Start Date*: 2016-08-30 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid Tumors | |||||||||||||
Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004178-10 | Sponsor Protocol Number: 20040104 | Start Date*: 2005-01-11 | |||||||||||
Sponsor Name:Amgen Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for ... | |||||||||||||
Medical condition: Chronic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SE (Completed) CZ (Completed) GB (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005807-32 | Sponsor Protocol Number: OTA105256 | Start Date*: 2007-06-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and the ph... | |||||||||||||
Medical condition: Uncomplicated preterm labour | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) LT (Prematurely Ended) ES (Completed) FR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024423-24 | Sponsor Protocol Number: AB10015 | Start Date*: 2013-01-29 | |||||||||||
Sponsor Name:ABScience | |||||||||||||
Full Title: A prospective, multicenter, randomized, double-blind, placebocontrolled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients su... | |||||||||||||
Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Completed) SK (Prohibited by CA) IT (Completed) HU (Completed) PT (Completed) IE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000827-25 | Sponsor Protocol Number: AZ3110866 | Start Date*: 2009-01-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: Study AZ3110866, a fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer's disease | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
